NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)
The shareholders in BioArctic AB (publ), corporate identity number 556601-2679, (”the Company”) are hereby summoned to the Annual General Meeting to be held on Tuesday, ...
Press releases
Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018
Stockholm, Sweden, April 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2018 ...
BioArctic receives regulatory approval in Norway for a clinical study in patients with Complete Spinal Cord Injury
Stockholm, Sweden, March 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Norwegian Medicines Agency ...
BioArctic receives patent protection in Japan for a medical device for treatment of patients with Complete Spinal Cord Injury
Stockholm, Sweden, March 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) issued a notification to grant ...
BioArctic receives regulatory approval in Estonia for a clinical study in patients with Complete Spinal Cord Injury
Stockholm, Sweden, February 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Estonian State Agency ...
Full Year Report January – December 2017
Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...
Invitation to presentation of BioArctic’s Full Year Report 2017 on February 20, 2018
Stockholm, Sweden, February 5, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report 2017 for the period January – ...
BioArctic receives US patent protection for a method with a medical device for treatment of patients with Complete Spinal Cord Injury
Stockholm, Sweden, February 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) published an Issue ...
BioArctic announces that the Phase 2b study of BAN2401 in early Alzheimer´s Disease continues toward 18 month endpoint
Criteria for success at 12 month interim analysis of ADCOMS not met Study to remain blinded per protocol until final readout of comprehensive 18 month data
BioArctic presents Nomination Committee and publishes financial calendar 2018
Stockholm, Sweden, November 9, 2017 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 31, 2017 the members of ...
Interim Report January – September 2017
BioArctic listed on Nasdaq Stockholm Mid Cap. July - September 2017- Net sales for the period amounted to SEK 31.5 million (1.2). Operating profit amounted to SEK ...
EXERCISE OF OVER-ALLOTMENT OPTION AND END OF THE STABILIZATION PERIOD
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
Invitation to presentation of BioArctic’s Interim Report January – September 2017 on November 8
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) publishes the company’s Interim Report for the period January – September 2017 on November 8, 2017 at 08:00 a.m. ...
Change in the number of shares and votes in BioArctic AB (publ)
Stockholm, Sweden, October 31, 2017 – BioArctic AB (publ) (“BioArctic” or the “Company” ) today announced that the number of shares and votes in BioArctic has ...
Stabilization notice
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, is now granted in Europe
Stockholm, Sweden, October 13, 2017 – BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European ...
Trading in BioArctic’s B-shares commences today on Nasdaq Stockholm
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic AB publishes prospectus for initial public offering on Nasdaq Stockholm
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic AB intends to list on Nasdaq Stockholm
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research
BioArctic announced that it entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies ...
Pharmaceutical study starts in Sweden with BAN2401 in early Alzheimer patients
BioArctic Neuroscience AB today announced that the first patient in Sweden has been treated with BAN2401 in a clinical study aimed at patients with an early ...
BioArctic Neuroscience and Elos Medtech start collaboration on new treatment for spinal cord injuries
The Swedish biotech company BioArctic Neuroscience and the medtech company Elos Medtech have today signed a cooperation agreement for a new treatment of spinal cord injuries.
Drug Candidate Receives Orphan Drug Designation
The text below is a translation of a Swedish press release. BioArctic Neuroscience develops treatments to help victims of spinal cord injury. The European Medicines Agency ...
BioArctic Neuroscience and Swenora Biotech Enter Into Exclusive Licensing Agreement
Today the Swedish biotech companies BioArctic Neuroscience and Swenora Biotech have entered into an exclusive licensing agreement for a novel treatment of Spinal Cord Injury Treatment. ...
